BSE · 512101
Triochem Products Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹1 Cr with net profit ₹8 Cr — a 922% net margin, versus -38.12% the period before.
Shareholding
As of 2026-09-30
- Promoter68.65%
- Public31.35%
55 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 1× from low to high.
Risk flags
Derived from disclosed data
No flags raised by the data.
Peer comparison
Pharmaceuticals - Indian - Bulk Drugs & Formln · ranked #96 of 102 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd. | ₹4,51,075 Cr | 36.65 | 5.05 | 13.79% | 17.89% |
| Laurus Labs Limited | ₹1,30,972 Cr | 97.74 | 21.57 | 22.11% | 17.13% |
| Zydus Lifesciences Ltd. | ₹1,18,693 Cr | 26.12 | 4.27 | 15.1% | 14.11% |
| Dr Reddys Laboratories Ltd. | ₹1,15,267 Cr | 41.17 | 2.96 | 7.21% | 8.49% |
| Cipla Ltd. | ₹1,12,442 Cr | 36.21 | 3.18 | 8.18% | 10.39% |
| Mankind Pharma Limited | ₹1,09,044 Cr | 46.73 | 6.23 | 12.76% | 14.58% |
| Aurobindo Pharma Ltd. | ₹1,04,903 Cr | 25.85 | 2.67 | 10.13% | 10.88% |
| Lupin Limited | ₹90,558 Cr | 16.07 | 3.76 | 21.65% | 17.07% |
| Glenmark Pharmaceuticals Ltd. | ₹74,507 Cr | 36.78 | 6.65 | 18.07% | 9.22% |
| Alkem Laboratories Ltd. | ₹61,146 Cr | 28.2 | 4.11 | 13.91% | 13.23% |
| Triochem Products Ltd.(this company) | ₹0 Cr | — | 0.02 | -60.56% | 0% |
AI analysis
AI-generated · google/gemini-2.5-flashTriochem Products Ltd. is listed on the Indian markets. The company reported a revenue of Rs 1.05 Cr and a profit margin of 0% for the most recent period. Its book value is Rs 842.65.
Positives
- +The debt-to-equity ratio is 0.00, indicating no debt.
- +Promoter shareholding is substantial at 68.65% as on June 30, 2026.
- +There are no pledged shares by the promoters.
Negatives
- −Revenue has significantly declined to Rs 1.05 Cr in Mar 2025 from Rs 14.07 Cr in Mar 2021.
- −The company has reported negative Net Profit for Mar 2025 at -Rs 0.40 Cr.
- −Return on Equity (ROE) is significantly negative at -314.1%.
- −Return on Capital Employed (ROCE) is negative at -2.76%.
- −Quarterly results have consistently shown zero revenue since Dec 2024.
Financial performance
Triochem Products Ltd. reported a revenue of Rs 1.05 Cr for Mar 2025. This marks a decline from its revenue of Rs 14.07 Cr in Mar 2021. The company's net profit was -Rs 0.40 Cr in Mar 2025, following a net profit of Rs 1.32 Cr in Mar 2022. The Earnings Per Share (EPS) for Mar 2025 was -Rs 16.33.
Profitability & returns
The company's Return on Equity (ROE) is -314.1%, and its Return on Capital Employed (ROCE) is -2.76%. For Mar 2025, the profit margin was 0%. EBITDA for Mar 2025 was -Rs 0.25 Cr, a decrease from Rs 1.78 Cr in Mar 2022.
Balance sheet
Triochem Products Ltd. has a debt-to-equity ratio of 0.00, indicating no debt. The book value per share stands at Rs 842.65. No market capitalization figure is available for the company.
Ownership & pledges
Public shareholding is 31.35%, distributed among 55 shareholders. There are no shares pledged by the promoters.
Data as of — price: 2026-11-14 · financials: Mar 26 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.